Novo Nordisk has published the primary results of its phase 3 STEP Young trial, which tested once-weekly semaglutide injections in children aged 6 to under 12 who live with obesity. The data were presented at ObesityWeek 2026 in Washington, D.C., and published in The New England Journal of Medicine on 18 November. In the trial’s efficacy analysis, almost 80% of children on semaglutide cut their BMI by at least 10% after 68 weeks. No child on placebo did.
What the trial found
STEP Young enrolled 165 children in a randomised, double-blind, placebo-controlled, multinational design. All of them also followed a reduced-calorie diet and increased their physical activity. More than 85% had class II or III severe obesity at the start, meaning a BMI of at least 35 kg/m² or 40 kg/m² respectively.
Novo reports two ways of looking at the 68-week data. The first is the treatment regimen estimand, which counts children whether or not they stayed on treatment. The second is the efficacy estimand, which models what happens if everyone stays on treatment and uses no other weight-management intervention.
- Average BMI change: -13.5% with semaglutide against +2.7% with placebo (treatment regimen). In the efficacy analysis it was -17.4% against +2.2%. The treatment differences were -16.2 percentage points (95% CI -19.4 to -12.9; p<0.001) and -19.7 (95% CI -23.1 to -16.2).
- BMI reduction of 10% or more: 78.7% with semaglutide against 0% with placebo in the efficacy analysis. Regardless of adherence, the figures were 74.7% against 4.3%.
- Improvement in BMI category: 83.0% against 23.5% in the efficacy analysis, and 78.8% against 23.4% regardless of adherence.
- No longer classed as having obesity: 40.4% against 0% in the efficacy analysis, and 38.4% against 2.1% regardless of adherence.
At week 104, BMI had changed by -9.4% with semaglutide and +8.4% with placebo (treatment regimen), or -14.0% and +5.7% in the efficacy analysis. Novo notes that the week-104 results were not adjusted for multiplicity and can’t be used for statistical inference.
Dosing and trial timeline
Children received a maximum dose of 1.7 mg or 2.4 mg, depending on baseline weight. The 2.4 mg ceiling applied to those above 60 kg, and 1.7 mg to those weighing 45–60 kg, or the maximum tolerated dose. The trial began in July 2023. The week-68 primary endpoint was reached in October 2025, end of treatment at week 104 in May 2026, and a seven-week off-drug safety follow-up finished in July 2026.
Safety and regulatory status
Novo says the safety and tolerability profile matched its earlier paediatric and adult semaglutide trials, with no unexpected safety concerns. It also reports no concerns for growth or pubertal development. Semaglutide 2.4 mg carries a boxed warning for possible thyroid tumours, including cancer. It should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The most common side effects include nausea, diarrhoea, vomiting, constipation and abdominal pain.
The treatment is still investigational for this age group. It is not approved in the US for children under 12, and Novo says there is no guarantee it will become commercially available for this use.
“The STEP Young results highlight the potential of semaglutide, alongside lifestyle modifications, in improving obesity care for children who need medical treatment,” said Martin Holst Lange, executive vice president, R&D and Chief Scientific Officer at Novo Nordisk.
The World Obesity Federation’s World Obesity Atlas 2026 estimated that around 177 million children and teenagers aged 5 to 19 were living with obesity worldwide in 2025.
